The estimated Net Worth of Michael Morneau is at least $6.54 millió dollars as of 31 May 2018. Mr. Morneau owns over 21,551 units of Viking Therapeutics Inc stock worth over $5,720,149 and over the last 10 years he sold VKTX stock worth over $199,347. In addition, he makes $619,564 as Vice President - Finance and Administration at Viking Therapeutics Inc.
Sign up
Mr. Morneau VKTX stock SEC Form 4 insiders trading
Michael has made over 1 trades of the Viking Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 21,551 units of VKTX stock worth $199,347 on 31 May 2018.
The largest trade he's ever made was selling 21,551 units of Viking Therapeutics Inc stock on 31 May 2018 worth over $199,347. On average, Michael trades about 1,078 units every 0 days since 2015. As of 31 May 2018 he still owns at least 94,035 units of Viking Therapeutics Inc stock.
You can see the complete history of Mr. Morneau stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Morneau biography
Michael Morneau CPA serves as Vice President - Finance and Administration of the Company. Mr. Morneau has over 20 years of accounting and financial experience at public and private companies in the biotechnology and accounting industries. Prior to Viking, from 2009 to 2014, he was VP of Finance and Chief Accounting Officer at Trius Therapeutics, Inc., a subsidiary of Cubist Pharmaceuticals, Inc., a pharmaceutical company, following Cubist’s acquisition of Trius in September 2013. Prior to Trius, from 2008 to 2009, he was Director of Lilly Research Labs Finance at Eli Lilly and Company, a pharmaceutical company. Prior to Eli Lilly, from 2006 to 2008, he was Director of Finance and Accounting at SGX Pharmaceuticals, Inc., a biotechnology company, which was acquired by Eli Lilly. Prior to SGX, from 2004 to 2006, he was Controller at Momenta Pharmaceuticals, Inc., a biotechnology company. Mr. Morneau earned his MBA and MA in accounting from New Hampshire College, and a BA in mathematics from the University of New Hampshire.
What is the salary of Michael Morneau?
As the Vice President - Finance and Administration of Viking Therapeutics Inc, the total compensation of Michael Morneau at Viking Therapeutics Inc is $619,564. There are 2 executives at Viking Therapeutics Inc getting paid more, with Brian Lian having the highest compensation of $3,512,120.
What's Michael Morneau's mailing address?
Michael's mailing address filed with the SEC is C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, SUITE 250, SAN DIEGO, CA, 92130.
Insiders trading at Viking Therapeutics Inc
Over the last 10 years, insiders at Viking Therapeutics Inc have traded over $46,107,976 worth of Viking Therapeutics Inc stock and bought 199,715 units worth $855,627 . The most active insiders traders include Brian Lian, Charles A Jr Rowland és Marianna Mancini. On average, Viking Therapeutics Inc executives and independent directors trade stock every 75 days with the average trade being worth of $4,137,170. The most recent stock trade was executed by Brian Lian on 21 August 2024, trading 1,000 units of VKTX stock currently worth $7,770.
What does Viking Therapeutics Inc's logo look like?
Complete history of Mr. Morneau stock trades at Viking Therapeutics Inc
Viking Therapeutics Inc executives and stock owners
Viking Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Brian Lian,
President, Chief Executive Officer, Director -
Dr. Brian Lian Ph.D.,
Pres, CEO & Director -
Michael Morneau,
Vice President - Finance and Administration -
S. Kathy Rouan,
Independent Director -
Lawson Macartney,
Independent Chairman of the Board -
Charles Rowland,
Independent Director -
J. Matthew Singleton,
Independent Director -
Matthew Foehr,
Director -
Greg Zante,
Senior Vice President - Finance, IR Contact Officer -
Michael Morneau,
VP of Fin. & Admin. -
Marianne Mancini,
Chief Operating Officer -
Gregory S. Zante,
Chief Financial Officer -
Pharmaceuticals Inc Ligand,
10% owner -
Stephen W Webster,
Director -
Rochelle Hanley,
Chief Medical Officer -
Hiroko Masamune,
Chief Development Officer -
Marianna Mancini,
Chief Operating Officer -
Michael Dinerman,
Chief Operating Officer